Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumor Refractory to Conventional Treatment”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Early research (Phase 1)Study completedNCT00658970
What this trial is testing

Evaluation of KX2-391 in Patients With Advanced Malignancies

Who this might be right for
Solid TumorsLymphoma
Athenex, Inc. 50
Early research (Phase 1)Not Yet RecruitingNCT07345637
What this trial is testing

Phase I Study of FXS887 in the Treatment of Solid Tumors

Who this might be right for
Solid Tumor Refractory to Conventional Treatment
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 14
Early research (Phase 1)Study completedNCT03941262
What this trial is testing

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Who this might be right for
Refractory CancerMetastatic CancerRecurrent Cancer+4 more
NKGen Biotech, Inc. 27
Testing effectiveness (Phase 2)Study completedNCT00003173
What this trial is testing

High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsChildhood Germ Cell TumorExtragonadal Germ Cell Tumor+5 more
Memorial Sloan Kettering Cancer Center 36
Testing effectiveness (Phase 2)Looking for participantsNCT06607692
What this trial is testing

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Who this might be right for
Solid Tumor CancerMedulloblastomaHigh Risk Neuroblastoma+17 more
Fundación de investigación HM 25
Early research (Phase 1)UnknownNCT02223923
What this trial is testing

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours

Who this might be right for
Solid Tumour Refractory to Conventional Treatment
Royal Marsden NHS Foundation Trust 87
Early research (Phase 1)Study completedNCT05990920
What this trial is testing

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Who this might be right for
Pathologically Confirmed Cancer Refractory to Conventional TherapyRefractory CancerMetastatic Cancer+5 more
NKGen Biotech, Inc. 6
Early research (Phase 1)Study completedNCT00646139
What this trial is testing

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Who this might be right for
LymphomaLymphoproliferative DisorderSmall Intestine Cancer+1 more
Roswell Park Cancer Institute 7